Peripheral artery disease (PAD) is the most common manifestation of cardiovascular disease in the lower limbs. Advanced PAD severely diminishes quality of life, affecting patients’ mobility and, in its most severe form leads to limb amputation and death. In diabetic patients, where advanced PAD often manifests below the knee, the downward spiral of chronic limb-threatening ischemia, tissue loss and amputation, is intractable. Current therapies have major drawbacks that limit their effectiveness.
We have developed a minimally invasive treatment for PAD that leaves no permanent device behind that is based on a new nanoparticle invented by the team at Nanomedx. The nanoparticles increase drug efficacy in blood vessels, and in this project carry a human protein that switches off local inflammation. We have engineered a new device to locally deliver our therapy to areas of disease. This grant will facilitate the advancement of our approach to first-in-human trials.
